Latest news with #SunPharmaAdvancedResearchCompany
Business Standard
04-08-2025
- Business
- Business Standard
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 51.87 crore in the June 2025 quarter
Sales decline 42.65% to Rs 9.64 croreNet Loss of Sun Pharma Advanced Research Company reported to Rs 51.87 crore in the quarter ended June 2025 as against net loss of Rs 95.90 crore during the previous quarter ended June 2024. Sales declined 42.65% to Rs 9.64 crore in the quarter ended June 2025 as against Rs 16.81 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% -43 OPM %-540.25-555.38 -PBDT-49.13-92.36 47 PBT-51.81-95.50 46 NP-51.87-95.90 46 Powered by Capital Market - Live News
Business Upturn
04-08-2025
- Business
- Business Upturn
Sun Pharma Advanced Research Q1 Results: Net loss narrows to Rs 51.8 crore, Revenue drops 42.6% YoY
Sun Pharma Advanced Research Company (SPARC) reported a consolidated net loss of Rs 51.8 crore for the quarter ended June 30, 2025 (Q1 FY26), significantly narrowing from the loss of Rs 95.9 crore in Q1 FY25. However, the company remained in the red for the quarter. Total income for Q1 FY26 stood at Rs 18.78 crore, down 42.6% from Rs 31.37 crore reported in the same quarter last year. Revenue from operations dropped to Rs 9.64 crore from Rs 16.81 crore year-on-year, reflecting a continued decline in licensing income and product revenues. Expenses for the quarter came in at Rs 70.59 crore, down from Rs 113.87 crore in Q1 FY25. The reduction in employee costs and clinical trial expenditure contributed to the lower overall expense base. Despite cost optimization, the company posted a pre-tax loss of Rs 51.8 crore compared to Rs 95.5 crore loss a year earlier. Tax expense for the quarter stood at Rs 6 lakh. SPARC continues to invest in R&D and drug development, which significantly contributes to its expense structure and quarterly volatility. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
04-06-2025
- Business
- Business Standard
SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials
Sun Pharma Advanced Research Company (SPARC) dropped 18.63% to Rs 159.15 after the company announced disappointing results from a key clinical trial. In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025.
&w=3840&q=100)
Business Standard
04-06-2025
- Business
- Business Standard
Sun Pharma Advanced Research hits 20% lower band; what's rattling Street?
Sun Pharma Advanced Research Company (SPARC) shares slumped 20 per cent in trade on Wednesday, June 4, 2025, hitting its lower circuit at ₹156.5 per share on BSE. The stock was under pressure after the company's partner Sun Pharmaceutical Industries informed that its phase 2 trial for evaluating SOLARES PsO and SOLARES AD studies failed to meet the primary endpoint. In the past one year, Sun Pharma Advanced Research Company shares have declined 3 per cent as compared to Sensex's rise of around 12 per cent. At 9:36 AM, Sun Pharma Advanced Research share price was down 15.16 per cent at ₹165.95 per share on the BSE. In comparison, the BSE Sensex was up 0.04 per cent at 80,766.66. The market capitalisation of the company stood at ₹5,385.44 crore. The 52-week high of the stock was at ₹257.7 per share and the 52-week low of the stock was at ₹109.2 per share. Why did Sun Pharma Advanced Research stock tanked? The company released a filing on Tuesday, after market hours, in which it said that the phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD) failed to meet primary endpoint of 75 per cent improvement in Psoriasis Area and Severity Index (PASI). "SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD). SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16 respectively," the filing read. It added: SPARC and SPIL will evaluate the appropriate next steps for SCD-044. Psoriasis is a chronic autoimmune condition characterised by skin inflammation and accelerated skin cell growth, resulting in raised, scaly patches called plaques, most commonly on the elbows, knees, scalp, and trunk. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterised by dry, itchy, and inflamed skin. It's a long-term condition that can cause patchy rashes and can occur at any age, though it often begins in childhood.
Business Upturn
04-06-2025
- Business
- Business Upturn
SPARC shares drop nearly 20% after key drug trial fails
By Aman Shukla Published on June 4, 2025, 11:35 IST Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044). The drop came following an update from Sun Pharmaceutical Industries Limited, SPARC's collaborator, which revealed that the Phase 2 trials for Vibozilimod failed to meet their primary efficacy endpoints. The drug, which was being tested for treating moderate-to-severe psoriasis and atopic dermatitis, did not show the required 75% improvement in PASI and EASI scores by Week 16. As a result, no further trials will be conducted, marking a significant setback for both companies' specialty drug pipelines. Shares of Sun Pharma Advanced Research Company (SPARC) opened at ₹185.00 and touched an intraday low of ₹156.14, reflecting a sharp decline. The stock did not move above its opening price, indicating bearish sentiment. SPARC is currently trading closer to its 52-week low of ₹109.30, far below the 52-week high of ₹258.00. As of 11:34 AM, the shares were trading 17.95% lower at Rs 160.15. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
